Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,047 mentions
- robotic manipulationmarket829 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology352 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
paroxysmal nocturnal hemoglobinuria treatment
market3 mentionslast seen Nov 9, 2026
Treatment of paroxysmal nocturnal hemoglobinuria.
Relationships 2
Relationship
vensobafusp alfaapplies toparoxysmal nocturnal hemoglobinuria treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 9, 2026Jasper Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Vensobafusp alfa is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH)
- filingSEC EDGAROct 15, 2026Jasper Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
has been granted Orphan Drug Designation by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)